Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Multiple Ascending Doses of PF-07328948 in Healthy Adults
NCT05807490Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of PF-07328948 in heart failure (HF) (11 cohorts), sponsored by Pfizer. Primary endpoints: Treatment Emergent Treatment-Related Adverse Events, Clinical Laboratory Abnormalities and 6 more. Started Apr 2023; status: completed.
02
Drugs
PF-07328948
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05807490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807490.